Merck & Co. Inc. (MRK): Price and Financial Metrics

Merck & Co. Inc. (MRK): $81.66

0.51 (+0.63%)

POWR Rating

Component Grades














  • MRK scores best on the Value dimension, with a Value rank ahead of 85.93% of US stocks.
  • MRK's strongest trending metric is Quality; it's been moving down over the last 52 weeks.
  • MRK ranks lowest in Momentum; there it ranks in the 18th percentile.

MRK Stock Summary

  • MRK has a higher market value than 98.91% of US stocks; more precisely, its current market capitalization is $205,471,684,074.
  • MRK's went public 35.83 years ago, making it older than 92.68% of listed US stocks we're tracking.
  • In terms of volatility of its share price, MRK is more volatile than just 0.57% of stocks we're observing.
  • Stocks that are quantitatively similar to MRK, based on their financial statements, market capitalization, and price volatility, are LLY, INTC, TXN, PFE, and NVS.
  • MRK's SEC filings can be seen here. And to visit Merck & Co Inc's official web site, go to

MRK Valuation Summary

  • MRK's price/earnings ratio is 34.7; this is 4.93% lower than that of the median Healthcare stock.
  • Over the past 243 months, MRK's price/sales ratio has gone up 0.7.
  • Over the past 243 months, MRK's price/sales ratio has gone up 0.7.

Below are key valuation metrics over time for MRK.

Stock Date P/S P/B P/E EV/EBIT
MRK 2021-08-31 4.0 5.8 34.7 30.5
MRK 2021-08-30 4.0 5.8 34.8 30.5
MRK 2021-08-27 4.0 5.8 34.7 30.5
MRK 2021-08-26 4.0 5.8 34.8 30.6
MRK 2021-08-25 4.0 5.9 35.0 30.7
MRK 2021-08-24 4.1 5.9 35.3 31.0

MRK Growth Metrics

  • The year over year net cashflow from operations growth rate now stands at -11.51%.
  • Its 5 year price growth rate is now at 52.29%.
  • The 5 year net cashflow from operations growth rate now stands at 3.14%.
Over the past 30 months, MRK's revenue has gone up $6,254,000,000.

The table below shows MRK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 48,548 10,460 5,571
2021-03-31 48,018 11,337 7,028
2020-12-31 47,994 10,253 7,067
2020-09-30 47,348 11,041 11,518
2020-06-30 47,194 13,094 10,478
2020-03-31 48,082 12,811 10,146

MRK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRK has a Quality Grade of B, ranking ahead of 77.69% of graded US stocks.
  • MRK's asset turnover comes in at 0.535 -- ranking 77th of 681 Pharmaceutical Products stocks.
  • XTNT, ACOR, and NBIX are the stocks whose asset turnover ratios are most correlated with MRK.

The table below shows MRK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.535 0.675 0.129
2021-03-31 0.529 0.670 0.158
2020-12-31 0.538 0.677 0.171
2020-09-30 0.542 0.712 0.276
2020-06-30 0.550 0.701 0.260
2020-03-31 0.571 0.701 0.256

MRK Price Target

For more insight on analysts targets of MRK, see our MRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $93.38 Average Broker Recommendation 1.52 (Moderate Buy)

MRK Stock Price Chart Interactive Chart >

Price chart for MRK

MRK Price/Volume Stats

Current price $81.66 52-week high $85.60
Prev. close $81.15 52-week low $70.89
Day low $79.95 Volume 9,365,800
Day high $81.73 Avg. volume 12,290,305
50-day MA $76.94 Dividend yield 3.2%
200-day MA $76.88 Market Cap 206.71B

Merck & Co. Inc. (MRK) Company Bio

Merck & Co., Inc.d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.(Source:Wikipedia)

MRK Latest News Stream

Event/Time News Detail
Loading, please wait...

MRK Latest Social Stream

Loading social stream, please wait...

View Full MRK Social Stream

Latest MRK News From Around the Web

Below are the latest news stories about Merck & Co Inc that investors may wish to consider to help them evaluate MRK as an investment opportunity.

Pfizer says vaccine is 90.7% effective in kids aged 5 to 11: BBG

Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Yahoo | October 22, 2021

Waltham cancer biotech goes public in $118M IPO

Xilio Therapeutics, the Waltham-based cancer biotech that rebranded from Akrevia Therapeutics back in early 2020, has made its Wall Street debut. The company raised $117.5 million in an IPO on Friday, selling nearly 7.4 million shares at $16 apiece.

Yahoo | October 22, 2021

Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.

Yahoo | October 22, 2021

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas Resigns Athira Pharma, Inc. (NASDAQ: ATHA) announced the appointment of Mark Litton, who was serving as the company's chief operating officer, as its chief executive officer. Litton succeeds Leen Kawas, who has resigned from her position as President and CEO and as a member of the company's board. Kawas was placed on leave af

Yahoo | October 22, 2021

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)

KENILWORTH, N.J., October 22, 2021--EC Approves Merck’s KEYTRUDA Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic TNBC

Yahoo | October 22, 2021

Read More 'MRK' Stories Here

MRK Price Returns

1-mo 10.94%
3-mo 5.19%
6-mo 12.79%
1-year 7.17%
3-year 27.09%
5-year 55.17%
YTD 2.48%
2020 -7.20%
2019 22.27%
2018 39.95%
2017 -1.49%
2016 15.05%

MRK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full MRK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8658 seconds.